$115.57
1.75% today
Nasdaq, Oct 07, 07:14 pm CET
ISIN
US3755581036
Symbol
GILD

Gilead Sciences Stock price

$113.58
-2.30 1.98% 1M
+8.06 7.64% 6M
+21.21 22.96% YTD
+29.15 34.53% 1Y
+48.63 74.87% 3Y
+51.06 81.67% 5Y
+16.04 16.44% 10Y
+102.20 898.07% 20Y
Nasdaq, Closing price Mon, Oct 06 2025
+0.89 0.79%
ISIN
US3755581036
Symbol
GILD
Industry

Key metrics

Basic
Market capitalization
$140.9b
Enterprise Value
$160.7b
Net debt
$19.7b
Cash
$5.2b
Shares outstanding
1.2b
Valuation (TTM | estimate)
P/E
22.6 | 13.8
P/S
4.9 | 4.8
EV/Sales
5.6 | 5.5
EV/FCF
17.6
P/B
7.2
Dividends
DPS
$3.08
Yield 1Y | 5Y
2.7% | 4.0%
Growth 1Y | 5Y
2.7% | 4.1%
Payout 1Y | 3Y
810.5% | 105.6%
Increased
10 Years
Financials (TTM | estimate)
Revenue
$28.9b | $29.3b
EBITDA
$15.2b | $14.8b
EBIT
$11.0b | $13.5b
Net Income
$6.3b | $10.3b
Free Cash Flow
$9.1b
Growth (TTM | estimate)
Revenue
3.8% | 2.1%
EBITDA
15.3% | 8.8%
EBIT
5.9% | 24.4%
Net Income
499.3% | 2,037.8%
Free Cash Flow
32.5%
Margin (TTM | estimate)
Gross
78.5%
EBITDA
52.5% | 50.4%
EBIT
38.1%
Net
21.9% | 35.0%
Free Cash Flow
31.7%
Financial Health
Equity Ratio
32.8%
Return on Equity
2.5%
ROCE
24.7%
ROIC
20.8%
Debt/Equity
1.3
More
EPS
$5.0
FCF per Share
$7.4
Short interest
1.5%
Employees
18k
Rev per Employee
$1.6m
Show more

Create a Free Account to create an Gilead Sciences alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Gilead Sciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

36 Analysts have issued a Gilead Sciences forecast:

28x Buy
78%
8x Hold
22%

Analyst Opinions

36 Analysts have issued a Gilead Sciences forecast:

Buy
78%
Hold
22%

Financial data from Gilead Sciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
28,863 28,863
4% 4%
100%
- Direct Costs 6,196 6,196
1% 1%
21%
22,667 22,667
5% 5%
79%
- Selling and Administrative Expenses 5,846 5,846
5% 5%
20%
- Research and Development Expense 5,818 5,818
4% 4%
20%
15,158 15,158
15% 15%
53%
- Depreciation and Amortization 4,154 4,154
51% 51%
14%
EBIT (Operating Income) EBIT 11,004 11,004
6% 6%
38%
Net Profit 6,311 6,311
499% 499%
22%

In millions USD.

Don't miss a Thing! We will send you all news about Gilead Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gilead Sciences Stock News

Positive
Seeking Alpha
one day ago
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their po...
Positive
Investors Business Daily
one day ago
Gilead stock popped Monday after the biotech giant said it signed deals with three generic drugmakers to delay their Biktarvy copycats.
Positive
The Motley Fool
3 days ago
Equity markets experienced significant volatility this year. Many investors feared that President Donald Trump's aggressive trade policies would plunge the economy into a recession and lead to a full-blown stock-market meltdown.
More Gilead Sciences News

Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.

Head office United States
CEO Daniel O'Day
Employees 17,600
Founded 1987
Website www.gilead.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today